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INTRODUCTION
Acute intermittent porphyria is an autosomal dominant
disease that results from defects in the enzyme
porphobilinogen-deaminase and manifests itself by
abdominal pain, neuropathies, and constipation, but,
unlike most types of porphyria, patients with it do not
have a rash. It is the most common and most severe of
the inherited hepatic porphyrias.4 The predominant
problem appears to be neurologic damage that leads to
peripheral and autonomic neuropathies and psychiatric
manifestations. The sequence of events in attacks is
usually (1) abdominal pain, (2) psychiatric symptoms
and (3) peripheral neuropathies, mainly motor
neuropathies. The neurovisceral symptoms result from
autonomic neuropathies (e.g. constipation, colicky
abdominal pain, vomiting and hypertension), peripheral
neuropathy, seizures, delirium, coma and depression.5
In most European countries, about 1 in 75000 people
suffer from it. The incidence in local adult or paediatric
population is unknown. We present a family, diagnosed
with acute intermittent porphyria.
CASE REPORT
A 13 years old girl came to our O.P.D. with the
complaints of abdominal pain, vomiting, restlessness
and jaundice for 5 days. On examination, she was
conscious but very irritable, anemic and jaundiced.
Vitals showed a blood pressure of 145/95 mmHg which
was above the 95th centile for age and sex. Systemic
examination was normal. Her family history was very
significant as her mother, maternal grandfather, three
maternal aunts and two maternal uncles have been
diagnosed as acute intermittent porphyria (Figure 1).
The girl was asked about the color of her urine and
she confirmed that it was red. She was investigated and
her labs showed a normal Hb: T.L.C: and platelets
count normal. Electrolytes showed a low sodium of
122 mmol/l. Potassium: 4 mmol/l, bicarbonate:
18 mmol/l, chloride: 98 mmol/l, Calcium: 9.3mg/dl and
phosphorus: 3mg/dl. Her urine was positive for ALA
(Amino-Levulinic Acid) and porphobilinogen. She was
managed with intravenous dextrose, hyponatremia was
corrected and propanolol was given for high blood
pressure. She was given an adequate calorie diet and
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CASE REPORT
Figure 1:  Family tree of acute intermittent porphyria.
her symptoms and color of urine improved. She was
discharged after 4 days of treatment with the advice for
a regular follow-up and to avoid long hours of fasting.
After discharge, she had two more admissions 3 months
apart with similar complaints and it was noted that they
coincided with the onset of her menstrual cycle. She
was also given a card with the diagnosis and a list of
drugs to be avoided.
DISCUSSION
Acute intermittent porphyria is characterized clinically by
acute episodes of a variety of gastrointestinal and
neuropathic symptoms; between episodes, the patient is
healthy. Abdominal pain is the most common presenting
symptom, sometimes with constipation and urinary
retention; paresthesias and paralysis also occur, and
death may result from respiratory paralysis. Acute
attacks rarely occur before puberty and they may be
precipitated by porphyrinogenic drugs such as
barbiturates, sulfonamides, carbamazepine, spirono-
lactone, diclofenac and many others, some of which are
known to induce the earlier rate-controlling step in heme
synthesis.8 About 1% of acute attacks of porphyria may
be fatal. Other known precipitants are alcohol, infection,
starvation, and hormonal changes; attacks are more
common in women.
Our patient was noted to have premenstrual attacks of
acute intermittent porphyria and during admissions had
hypertension and hyponatremia which needed
treatment during that period. Her irritability was because
of hypertension and hyponatremia, which resolved
when treated. With menstrually related attacks, attempts
to regulate the cycles with hormonal preparations may
exacerbate porphyria. Some patients have responded
well to hormonal suppression with gonadotrophin-
releasing hormone agonists, but the safety and efficacy
of different regimens need further investigation.10 Study
of patient’s suspected of having porphyria should
include several steps: (1) clinical evaluation, (2)
biochemical study, which enables us to classify the
patient to a specific form of porphyria, followed if
possible by (3) enzymatic assay(s), and (4) genetic
studies to confirm an enzyme deficiency and its level
and the causal genetic mutation. Unfortunately, enzyme
assays and genetic studies are not available in our
setup. Urinary estimation of porphobilinogen is the first
step if acute porphyria is suspected. In severe attacks, a
10% glucose infusion is commenced to provide a
minimum 300-400 g of carbohydrate/day which helps in
recovery.6 Hematin and haem arginate are the drugs of
choice, administered intravenously as a short infusion at
a dose of 3 mg/kg for 4 days and needs to be given early
to be effective. These drugs are not curative but shorten
and reduce the intensity of attack. If any drug has
caused the attack then it should be discontinued. The
pain which is extremely severe may require narcotic
analgesics.7 Infection should be treated and
hyponatremia which occurs as a result of dehydration,
nephrotoxicity or occasionally inappropriate antidiuretic
hormone secretion requires correction as it may cause
convulsions. Seizures often accompany this disease
and treatment can be problematic. The knowledge of
convulsions in acute intermittent porphyria is very
essential because the use of enzyme-inducing
antiepileptic drugs can cause worsening of the
convulsion leading to death.9
Thus, a strong clinical suspicion, early diagnosis and
adequate management of convulsions and prevention of
further attacks are of paramount importance in reducing
the morbidity and mortality. Prompt diagnosis and
treatment greatly improves prognosis and may prevent
development of severe or chronic neuropathic
symptoms. Prevention is important in acute intermittent
porphyria, especially in girls as females are more prone
to attacks and also have more severe symptoms than
males. Information should begin before puberty as
attacks in girls are likely to start at that time.
Unfortunately, no curative treatment is available for
any of the porphyrias.9 Patients should wear a medic
alert bracelet and should be fully educated regarding
precipitating factors. They should be evaluated by a
nutritionist and follow a well balanced diet with sufficient
calories to maintain weight. People with porphyria can
lead a normal life and the risk of acute attack decreases
after forty, but never disappears. When a patient is
diagnosed with porphyria, the whole family needs to be
screened.
Acute intermittent porphyria should always be
considered as the differential diagnosis in a case of
acute abdominal pain with neuropsychiatric
manifestations, whether family history of it is present
or not.
REFERENCES
1. Thadani H, Deacon A, Peters T. Diagnosis and management of
porphyria. BMJ 2000; 320:1647-51.
2. Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach
CA, Pimstone NR, et al. Recommendations for the diagnosis and
treatment of the acute porphyrias.  Ann Intern Med 2005; 142:
439-50.
3. Lecha M, Herrero C, Ozalla D. Diagnosis and treatment of the
hepatic porphyrias. Dermatol Ther 2003; 16: 65-72.
4. Kuo HC, Lee MJ, Chuang WL, Huang CC. Acute intermittent
porphyria with peripheral neuropathy: a follow-up study after
hematin treatment. J Neurol Sci 2007; 260: 231-5.
5. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias:
pathogenesis of neurological manifestations. Semin Liver Dis 1998;
18: 43-52.
6. Sies C, Florkowski C, George P, Potter H. Clinical indications for
the investigation of porphyria: case examples and evolving
laboratory approaches to its diagnosis in New Zealand. N Z Med J
2005; 118 (1222):U1658.
Journal of the College of Physicians and Surgeons Pakistan  2008, Vol. 18 (5): 316-318 317
A family with acute intermittent porphyria
7. De Loughery TG. Acute Intermittent porphyria. e medicine
[Inernet]. 2006 Jun 30 [cited 2008 Apr 30]. Available from:
http://www.emedicine.com/med/topic1880.htm
8. Sassa S. Modern diagnosis and management of porphyrias.
Br J Haematol 2006; 135: 281-92.
9. A safe and unsafe drugs in acute intermittent porphyria,
variegate porphyria and coproporphyria. In: Tobe BA, (edi)
Guide to porphyria. Manitoba, Canada: Canadian Porphyria
Foundation; 2003.
10. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotrophin
releasing hormone analogue prevents cyclical attacks of
porphyria. Arch Intern Med 1990; 150:1469-74
318 Journal of the College of Physicians and Surgeons Pakistan  2008, Vol. 18 (5): 316-318
Abdul Gaffar Billoo and Saira Waqar Lone
l l l l lOl l l l l
